LUND – Hansa Biopharma AB today announced a reorganization of its European and International Commercial and Medical Affairs operations, effective December 11, 2025. This action follows a comprehensive review of the European commercial operations over the past months, as referenced in the CEO letter of the Q3 Jan–Sept interim report. The review identified key areas…
LONDON: Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of molecular sensing technology based on nanopores, today announced the appointment of Francis Van Parys as Chief Executive Officer (“CEO”). Francis will join the Company and the Board as an Executive Director on 2 March 2026. Francis brings more than 20 years…
AMSTERDAM – Life sciences company QIAGEN NV said on Monday it has agreed to acquire Parse Biosciences, a provider of single-cell sequencing solutions, for an upfront $225 million in cash, aiming to capture a larger share of the fast-growing market for analyzing individual cells. The deal for the privately held U.S.-based company includes the potential…
STOCKHOLM: Swedish medical technology and life sciences investor MedCap AB on Friday reported a 32% rise in its third-quarter adjusted core earnings, driven by robust organic growth and contributions from recent acquisitions. The company, which buys and develops small- and medium-sized life science companies, said adjusted earnings before interest, taxes and amortisation (EBITA) rose to…
The manufacturing facility is expected to create 3,600 jobs WILMINGTON: AstraZeneca is investing $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500 million to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments. This is part of the historic $50 billion investment announced in July…
LONDON: International Biotechnology Trust PLC announced Wednesday it has entered into an agreement with Schroders Capital to establish a partnership aimed at investing in unquoted biotechnology companies. The new partnership is designed to provide the Company’s shareholders with long-term access to a diversified portfolio of earlier-stage, private biotechnology firms. The Company intends to make an…
PARIS: Sanofi Ventures has announced an additional $625 million multi-year capital commitment from Sanofi, increasing its total assets under management to over $1.4 billion. This new commitment to the evergreen venture fund builds on more than a decade of investing in innovative biotech and digital health companies that align with Sanofi’s long-term growth ambitions. “This…
LONDON: OptiBiotix Health plc (AIM: OPTI), a UK-based life sciences company focused on microbiome modulation and healthy sugar alternatives, reported a 35% increase in annual revenue for the year ending Dec. 31, 2024, signaling a strong turnaround bolstered by international expansion and ecommerce growth. Revenue rose to £870,000 from £644,000 in 2023, driven by increased…
LONDON: N4 Pharma plc (AIM: N4P), a UK-based biotechnology company developing its proprietary Nuvec® gene delivery system for advanced cancer and disease therapies, announced its audited financial results for the year ended Dec. 31, 2024. The company’s annual report and notice of its annual general meeting (AGM) have been distributed to shareholders. The AGM will…
SYDNEY, AUSTRALIA: ALS Limited (ASX: ALQ) today announced the acquisitions of Northeast USA-based York Analytical Laboratories and Europe-based Wessling Holding GmbH & Co. KG, supporting ALS’ strategic growth agenda in its Life Sciences portfolio, more specifically, the Environmental business. These acquisitions are expected to contribute ~A$195 million in revenues on a full-year basis. The total…
Agilent Technologies Inc. (NYSE: A) announced today that Padraig McDonnell, the current president of the Agilent CrossLab Group (ACG) and chief commercial officer, will succeed Mike McMullen as the company’s president and CEO on May 1. McMullen, who has been Agilent’s CEO since 2015 and has led the company’s transformation into a market leader in…
PARIS, FRANCE: Assystem S.A. has signed an agreement to sell its life sciences and general industry technical assistance businesses to Expleo Group. The enterprise value agreed between the parties is €28 million and the deal is scheduled to close on January 1, 2022. The agreement covers Assystem Care France, Assystem Belgium and Assystem Care Switzerland…